<DOC>
	<DOCNO>NCT01590901</DOCNO>
	<brief_summary>The Objectives study evaluate pharmacokinetics safety multiple oral dos probucol healthy male subject .</brief_summary>
	<brief_title>Pharmacokinetics Safety Study Probucol Multiple Administration Healthy Male Subjects</brief_title>
	<detailed_description>This single dose , single period , multiple administration , open-labeled trial one investigation center . The screening examination complete Day -14 Day -2 investigational medicinal product ( IMP ) administration . The subject hospitalize Day -1 . From Day 1 ( next day ) , subject receive probucol twice daily ( BID ) . 14 consecutive day . On Day 18 , subject discharge safety evaluation . The follow-up visit occur Day 6 , 9 , 12 , 15 , 19 , 27 ( totally 41 day ) final dosing day .</detailed_description>
	<mesh_term>Probucol</mesh_term>
	<criteria>1 . Chinese . 2 . Gender : Male . 3 . Age 20 40 year , ( time inform consent ) . 4 . Body mass index [ BMI , body weight ( kg ) / height ( ) 2 ] 19 26 kg/m2 , inclusive . 5 . Nonsmokers ( former smoker ) : Urinary cotinine level satisfy criterion nonsmoker establish trial site ( time screen examination ) . 6 . Subjects judge investigator healthy base medical history , physical examination , vital sign , 12 lead ECG , result serological test ( HIV/HCV Ab , HBsAg Syphilis Ab ) clinical laboratory test , etc . 1 . Subjects hypersensitivity history hypersensitivity drug ( prescription overthecounter [ OTC ] drug ) 2 . Subjects meet follow lipid criterion fast state ( time screen examination ) LDLC : ≥ 140 mg/dL TC : ≥ 220 mg/dL HDLC : &lt; 40 mg/dL TG : ≥ 150 mg/dL LDLC value directly measure calculate Friedewald formula . Friedewald Formula : LDLC = TC HDLC TG/5 ( When TG value le 400 mg/dL ) LDLC value directly measure TG value 400 mg/dL great . 3 . Subjects electrocardiogram ( ECG ) result show AV block QTc QRS width outside standard value ECG laboratory ( time screen examination ) 4 . Subjects alcohol drug dependence history drug abuse 5 . Subjects positive result infectious disease test urine drug test ( time screen examination ) 6 . Use follow within specified period prior schedule investigational medicinal product ( IMP ) administration All prescription OTC drug ( within 2 week prior schedule IMP administration ) Alcohol caffeinecontaining product ( within 1 week prior schedule IMP administration ) 7 . Use investigational drug within 16 week prior schedule IMP administration present trial 8 . Plasmapheresis plateletpheresis within 2 week whole blood collection ( blood donation , etc ) cumulatively exceed 200 mL within 4 week , 400 mL within 12 week , 1200 mL within 1 year prior schedule IMP administration 9 . Subjects whose body weight less 50 kg ( time screen examination ) 10 . Subjects schedule examination treatment hospital clinic trial period 11 . Subjects otherwise judge investigator sub investigator inappropriate inclusion trial</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Probucol</keyword>
	<keyword>healthy male subject</keyword>
</DOC>